The Angiotheragnostics team at @idibell_cat have identified a new therapeutic target to prevent anti-angiogenics resistance, as well as a plasma biomarker that selects patients that will benefit from the treatment.
#WorldCancerDay#CaixaImpulse
https://t.co/WWQyXehumg